Whole Blood Transcript Clusters for Ischemic Stroke Detection

Background:

Strokes result from reductions of blood flow to the brain and are second to coronary heart disease in terms of vascular disease incidence, morbidity, and mortality. About 83% of strokes are due to arterial vascular occlusion (ischemic stroke), and about 17% are due to vascular rupture (hemorrhagic stroke). Over the past 20 years, many scientific advances have been made in stroke diagnosis, treatment, and prevention; but important questions remain. Stroke diagnosis is inaccurate in up to 30% of patients, and it is not possible to reliably distinguish between ischemic and hemorrhagic stroke clinically. Clearly, a need exists for a panel of biomarkers associated with an increased risk of stroke.

Technology Overview:

This SUNY Downstate Health Sciences University technology provides biomarkers for the diagnosis and treatment of acute ischemic stroke. It also includes a quantitative assay method for accurately identifying the appropriate transcript number in a biological sample. This provides a method for identifying patients having an increased risk for developing acute ischemic stroke. For example, a biological sample can be obtained from the patient and used to determine the expression levels of at least three gene markers. The technology also provides a method for identifying agents useful for the treatment of acute ischemic stroke. Stage of Development Technology Readiness Level (TRL) 3 - Experimental proof of concept.

Advantages:

• More accurate diagnosis of stroke
• Identifies patients with increased risk for developing acute ischemic stroke
• Better distinguishing between ischemic stroke and hemorrhagic stroke

Applications:

Identifying patients with increased risk for acute stroke.

Intellectual Property Summary:

This technology is covered by the patent US 11021750 B2, Biomarkers for Predicting Risk of Acute Ischemic Stroke and Methods of Use Thereof.

Licensing Status:

This technology is available for licensing and will be of value to any company or institution involved in diagnosing and treating acute stroke. This includes:

• Manufacturers of medical test products
• Hospitals
• Rehabilitation facilities